Efficacy and safety of FLAG‐IDA as front‐line therapy in de novo paediatric acute myeloid leukaemia population.

All patients completed double induction with FLAG-IDA, and 27/30 (90%) patients completed all planned therapy (persistent thrombocytopenia, early relapse post-consolidation I, physician discretion). Of the 1096 patients enrolled in the COG trial AAML1031, MRD was available in 95% of patients and was negative (<0.05%) post-Induction I in only 75% of patients. Abbreviations AML Acute myeloid leukaemia ANC Absolute neutrophil count CNS Central nervous system COG Children's Oncology Group CR1 First complete remission EFS Event-free survival FLAG-IDA Fludarabine, cytarabine, idarubicin and G-CSF GO Gemtuzumab ozogamicin GCSF G-colony stimulating factor HDAc High-dose cytarabine HSCT Haematopoietic stem cell transplant IFI Invasive fungal infection LVSF Left ventricular shortening fraction MRC Medical Research Council MRD Minimal residual disease OS Overall survival TKI Tyrosine kinase inhibitor TRM Treatment-related mortality UK United Kingdom WBC White blood cell count DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. [Extracted from the article]